CMS-121

• Description:

  CMS-121 is a quinolone derivative and an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage with EC50 values of 7 nM and 200 nM, respectively. CMS-121 has strong neuroprotective, anti-inflammatory, antioxidative and renoprotective activities[1][2][3].

• UNSPSC:

  12352005

• Target:

  Acetyl-CoA Carboxylase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/cms-121.html

• Purity:

  99.63

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  OC1=CC=C(C2=NC3=CC=CC=C3C(OC4CCCC4)=C2)C=C1O

• Molecular Formula:

  C20H19NO3

• Molecular Weight:

  321.37

• References & Citations:

  [1]Currais A, et al. Elevating acetyl-CoA levels reduces aspects of brain aging. Elife. 2019 Nov 19;8. pii: e47866.|[2]Chiruta C, et al. Chemical modification of the multitarget neuroprotective compound fisetin. J Med Chem. 2012 Jan 12;55 (1) :378-89.|[3]Prior M, et al. Back to the future with phenotypic screening. ACS Chem Neurosci. 2014 Jul 16;5 (7) :503-13.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  1353224-53-9